Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod Open-Label Extension in Relapsing Multiple Sclerosis
NCT02576717Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of ozanimod in multiple sclerosis (MS), sponsored by Celgene Corporation. Primary endpoints: Number of Participants Experiencing Adverse Events (AEs), Number of Participants Experiencing Serious Adverse Events (SAEs) and 5 more. Started Oct 2015; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02576717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576717.